CN Patent

CN117659020A — 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Assigned to Suzhou Langrui Biopharmaceutical Co ltd · Expires 2024-03-08 · 2y expired

What this patent protects

本发明公开了一种式Ⅰ所示的咪唑并[1,2‑b]哒嗪衍生物，或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前体药、或其代谢物，以及该衍生物的药物组合物。所述式Ⅰ所示的咪唑并[1,2‑b]哒嗪衍生物或药物组合物可以作为TRK激酶抑制剂，用于治疗或预防由TRK或TRK突变介导的疾病或病症。

USPTO Abstract

本发明公开了一种式Ⅰ所示的咪唑并[1,2‑b]哒嗪衍生物，或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前体药、或其代谢物，以及该衍生物的药物组合物。所述式Ⅰ所示的咪唑并[1,2‑b]哒嗪衍生物或药物组合物可以作为TRK激酶抑制剂，用于治疗或预防由TRK或TRK突变介导的疾病或病症。

Drugs covered by this patent

Patent Metadata

Patent number
CN117659020A
Jurisdiction
CN
Classification
—
Expires
2024-03-08
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Langrui Biopharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.